TRCT
DSGN icon

Tower Research Capital (TRC)’s Design Therapeutics DSGN Stock Holding History

Tower Research Capital (TRC)’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71K Buy
4,908
+3,363
+218% +$41.9K ﹤0.01% 2462
2026
Q1 		$16.4K Sell
1,545
-2,728
-64% -$27.6K ﹤0.01% 3614
2025
Q4 		$40.1K Buy
4,273
+2,314
+118% +$18.1K ﹤0.01% 2594
2025
Q3 		$14.8K Sell
1,959
-7,739
-80% -$38.8K ﹤0.01% 3574
2025
Q2 		$32.7K Buy
9,698
+1,796
+23% +$6.72K ﹤0.01% 3335
2025
Q1 		$30.5K Buy
7,902
+6,141
+349% +$29.3K ﹤0.01% 2596
2024
Q4 		$10.9K Buy
1,761
+56
+3% +$324 ﹤0.01% 3770
2024
Q3 		$9.17K Sell
1,705
-4,337
-72% -$20.4K ﹤0.01% 3896
2024
Q2 		$20.2K Buy
6,042
+3,365
+126% +$13.1K ﹤0.01% 3760
2024
Q1 		$10.8K Sell
2,677
-18,826
-88% -$50.3K ﹤0.01% 3650
2023
Q4 		$57K Buy
21,503
+4,983
+30% +$11.4K ﹤0.01% 3044
2023
Q3 		$39K Buy
16,520
+11,220
+212% +$52.3K ﹤0.01% 2769
2023
Q2 		$33.4K Buy
5,300
+3,201
+153% +$19.6K ﹤0.01% 2929
2023
Q1 		$12K Sell
2,099
-1,142
-35% -$8.54K ﹤0.01% 4067
2022
Q4 		$33K Sell
3,241
-5,769
-64% -$78.2K ﹤0.01% 2657
2022
Q3 		$151K Buy
9,010
+2,951
+49% +$58.7K ﹤0.01% 2185
2022
Q2 		$85K Buy
6,059
+5,669
+1,454% +$76.6K ﹤0.01% 2414
2022
Q1 		$6K Sell
390
-881
-69% -$13.5K ﹤0.01% 4868
2021
Q4 		$27K Buy
1,271
+825
+185% +$14.2K ﹤0.01% 3338
2021
Q3 		$7K Sell
446
-1,683
-79% -$28K ﹤0.01% 4632
2021
Q2 		$42K Buy
2,129
+1,731
+435% +$43.7K ﹤0.01% 3168
2021
Q1 		$12K Buy
+398
New +$13.4K ﹤0.01% 4250

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s DSGN Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Design Therapeutics (DSGN) stake by 218% in Q2 2026, buying an estimated $41.9K and bringing the position to 4,908 shares worth $71K. The position accounts for ﹤0.01% of the portfolio, ranked #2462.

Tower Research Capital (TRC) first reported a position in DSGN in Q1 2021 and has held it in 22 quarters since. The position peaked at $151K in Q3 2022. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Tower Research Capital (TRC) held 4,908 shares of Design Therapeutics worth $71K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,363 Design Therapeutics shares in Q2 2026, an estimated $41.9K.
  • Design Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2462 holding.
  • Tower Research Capital (TRC) first reported a position in Design Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Design Therapeutics position peaked at $151K in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.